Vitamin B12 deficiency is common and affects cell division and differentiation, erythropoiesis, and the central nervous system. Several observational studies have demonstrated associations between biomarkers of vitamin B12 status with growth, neurodevelopment, and anemia. The objective of this study was to measure the effects of daily supplementation of vitamin B12 for 1 year on neurodevelopment, growth, and hemoglobin concentration in infants at risk of deficiency.
Methods and findings
This is a community-based, individually randomized, double-blind placebo-controlled trial conducted in low- to middle-income neighborhoods in Bhaktapur, Nepal. We enrolled 600 marginally stunted, 6- to 11-month-old infants between April 2015 and February 2017. Children were randomized in a 1:1 ratio to 2 μg of vitamin B12, corresponding to approximately 2 to 3 recommended daily allowances (RDAs) or a placebo daily for 12 months. Both groups were also given 15 other vitamins and minerals at around 1 RDA. The primary outcomes were neurodevelopment measured by the Bayley Scales of Infant and Toddler Development 3rd ed. (Bayley-III), attained growth, and hemoglobin concentration. Secondary outcomes included the metabolic response measured by plasma total homocysteine (tHcy) and methylmalonic acid (MMA). A total of 16 children (2.7%) in the vitamin B12 group and 10 children (1.7%) in the placebo group were lost to follow-up. Of note, 94% of the scheduled daily doses of vitamin B12 or placebo were reported to have been consumed (in part or completely). In this study, we observed that there were no effects of the intervention on the Bayley-III scores, growth, or hemoglobin concentration. Children in both groups grew on an average 12.5 cm (SD: 1.8), and the mean difference was 0.20 cm (95% confidence interval (CI): −0.23 to 0.63, P = 0.354). Furthermore, at the end of the study, the mean difference in hemoglobin concentration was 0.02 g/dL (95% CI: −1.33 to 1.37, P = 0.978), and the difference in the cognitive scaled scores was 0.16 (95% CI: −0.54 to 0.87, P = 0.648). The tHcy and MMA concentrations were 23% (95% CI: 17 to 30, P < 0.001) and 30% (95% CI: 15 to 46, P < 0.001) higher in the placebo group than in the vitamin B12 group, respectively. We observed 43 adverse events in 36 children, and these events were not associated with the intervention. In addition, 20 in the vitamin B12 group and 16 in the placebo group were hospitalized during the supplementation period. Important limitations of the study are that the strict inclusion criteria could limit the external validity and that the period of vitamin B12 supplementation might not have covered a critical window for infant growth or brain development.
In this study, we observed that vitamin B12 supplementation in young children at risk of vitamin B12 deficiency resulted in an improved metabolic response but did not affect neurodevelopment, growth, or hemoglobin concentration. Our results do not support widespread vitamin B12 supplementation in marginalized infants from low-income countries.
Why was this study done?
- Many marginalized children fail to reach their cognitive and growth potential.
- Subclinical vitamin B12 deficiency, which is poor vitamin B12 status without overt clinical symptoms, is common in this population in Nepal.
- Vitamin B12 deficiency in children is associated with anemia (low hemoglobin concentration), stunted growth, and poor neurodevelopment.
What did the researchers do and find?
- In this population-based, double-blind, randomized controlled trial (RCT), we measured the effects of daily supplementation of vitamin B12 for 1 year in 600 infants.
- The primary outcomes were neurodevelopment, growth, and hemoglobin concentration.
- We targeted stunted infants as these children are at risk of vitamin B12 deficiency.
- Daily supplementation of vitamin B12 for a year resulted in a metabolic profile reflecting substantially improved B12 status (lower total homocysteine (tHcy) and methylmalonic acid (MMA) concentrations) but did not affect neurodevelopment, growth, or hemoglobin concentration.
Citation: Strand TA, Ulak M, Hysing M, Ranjitkar S, Kvestad I, Shrestha M, et al. (2020) Effects of vitamin B12 supplementation on neurodevelopment and growth in Nepalese Infants: A randomized controlled trial. PLoS Med 17(12): e1003430. https://doi.org/10.1371/journal.pmed.1003430
Academic Editor: Lars Åke Persson, London School of Hygiene and Tropical Medicine, UNITED KINGDOM
Received: January 9, 2020; Accepted: October 23, 2020; Published: December 1, 2020
Copyright: © 2020 Strand et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: Data available on request. In order to meet ethical requirements for the use of confidential patient data, requests must be approved by the Nepal Health Research Council (NHRC) and the Regional Committee for Medical and Health Research Ethics in Norway. Requests for data should be sent to the authors, by contacting NHRC (http://nhrc.gov.np), or by contacting the Department of Global Health and Primary Care at the University of Bergen (email@example.com).
Funding: This study was funded by grants from the Thrasher Research Fund (award # 11512), and the South-Eastern Norway Regional Health Authority (grant # 2012090). TAS reports funding from the South-Eastern Norway Regional Health Authority (grant # 2012090), IK from the Research Council of Norway (grant # 234495), and MU from Thrasher Research Fund (award # 11512) for conducting this research. AMC and PMU are paid employees at Bevital AS. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: I have read the journal's policy and the authors of this manuscript have the following competing interests: AMC and PMU are paid employees at Bevital AS.
Abbreviations: Bayley-III, Bayley Scales of Infant and Toddler Development 3rd ed.; CI, confidence interval; CONSORT, CONsolidated Standards of Reporting Trials; GC-MS/MS, gas chromatography-tandem mass spectrometry; GMR, geometric mean ratio; GSDF, geometric standard deviation factor; ICC, intra-class correlation coefficient; id, identification; IMCI, Integrated Management of Childhood Illness; MMA, methylmalonic acid; NHRC, Nepal Health Research Council; RDA, recommended daily allowance; RCT, randomized controlled trial; REC, Regional Committee for Medical and Health Research Ethics; tHcy, total Homocysteine; 3cB12, combined indicator of cobalamin status
Vitamin B12 (cobalamin) deficiency is common and affects all ages worldwide [1–3]. Animal-based foods are the primary sources, and poor status is prevalent in South Asia as well as in other low- and middle-income regions with low consumption of meat, animal milk, and fish [3,4].
Vitamin B12 is required for cell division and differentiation, utilization of energy, and other critical metabolic processes [5–7]. Failure to thrive, delayed development, and macrocytic anemia are typical manifestations in children with severe deficiency . Several observational studies have demonstrated associations between biomarkers of vitamin B12 status with growth, neurodevelopment, and anemia [1,9–14]. The results from these studies suggest that the negative consequences of poor B12 nutrition are also seen in suboptimal B12 status, and not only in those with clinical deficiency. These observations, however, may be due to factors such as unmeasured confounding or limitations in the biomarkers used to assess vitamin B12 status.
Three randomized controlled trials (RCTs) have measured the effect of vitamin B12 supplementation on neurodevelopment in children with suboptimal B12 status. Of these, 2 facility-based RCTs in infants born at low birth weight or who had developmental delay showed that a high dose of vitamin B12 (400-μg hydroxycobalamin intramuscularly) substantially improved motor development [15,16]. In the third study, a population-based RCT in young North Indian children, there was a small borderline significant beneficial effect of daily oral supplementation with 1.8 μg of vitamin B12 for 6 months on neurodevelopment . The evidence from these RCTs support the notion that poor vitamin B12 status may be a relevant public health concern; however, the evidence is currently not strong enough to alter widespread feeding recommendations. We therefore designed the current population-based RCT to measure the effects of daily supplementation of vitamin B12 for 1 year. In this study, we ensured that the baseline B12 status and metabolic response to the supplementation was well characterized, and we targeted marginally stunted infants due to their associated risk of vitamin B12 deficiency, delayed development, and stunted growth.
Participants and methods
Study design and participants
This study is reported according to the CONsolidated Standards of Reporting Trials (CONSORT) guidelines (S1 Checklist). The study was a community-based, double-blind placebo-controlled trial in Nepalese infants. We hypothesized that daily administration of 2 μg vitamin B12 for 12 months would improve neurodevelopment, growth, and hemoglobin concentration. We conducted the study in Bhaktapur municipality and surrounding peri-urban communities near the capital Kathmandu. For the last 20 years, we have shown that poor vitamin B12 status is common in both women and children in this population [4,18,19]. Bhaktapur is among the most densely populated municipalities in Nepal. The majority of births (96%) occur at health centers, and 1 in every second family is living in joint households and has a separate kitchen . The primary outcomes were neurodevelopment measured by the Bayley Scales of Infant and Toddler Development 3rd ed. (Bayley-III), attained growth (cm and kg), and hemoglobin concentration. The secondary outcome was the metabolic response measured by plasma concentrations of cobalamin, total homocysteine (tHcy), and methylmalonic acid (MMA).
The study received ethical clearance from the Nepal Health Research Council (NHRC; #233/2014) and from the Regional Committee for Medical and Health Research Ethics (REC; #2014/1528) in Norway. After detailed information was provided to parents, we obtained written informed consent or a thumbprint from those who were illiterate (in the presence of an impartial witness).
Enrollment, randomization, and blinding
We enrolled 600 children between April 17, 2015 and February 15, 2017. Inclusion criteria were age 6 to 11 months, length for age z-score <−1, intent to reside in the municipality and surrounding areas for the next 12 months, and availability of informed consent from parents. Children were excluded if they were taking (or planned to take) supplements that contained vitamin B12, had a severe systemic illness requiring hospitalization, if they were severely malnourished (weight for length z-score <−3), were severely anemic (hemoglobin concentration <7 g/dL), or had ongoing infections that required medical treatment. In cases of severe malnutrition, anemia, or infections, children received treatment and were screened again for eligibility after recovery.
Field workers identified eligible children from immunization clinics or through home visits. Infants were enrolled by a study supervisor or by a physician at the field office. We randomized the infants in a 1:1 ratio in blocks of 8 using a computer-generated randomization list. Randomization was concealed, and the study double-blinded as the participants were only linked to the intervention through the identification (id) number printed on the supplement labels. The list that linked this id number to the randomization code was kept with the producers of the supplements and the scientist who generated it. None of the investigators had access to this list until the data collection and cleaning for the primary outcomes were completed. The vitamin B12 supplements and placebo were produced specifically for the trial and were identical in taste and appearance. At enrollment and end of study, we measured neurodevelopment, weight, length, and hemoglobin concentration.
Intervention and co-interventions
All children received 2 μg of vitamin B12 (cyanocobalamin), corresponding to approximately 2 to 3 recommended daily allowances (RDAs) or placebo via a daily oral supplement for 12 months. The intervention was implemented using sachets containing 20 grams of a lipid-based paste produced by GC Rieber Compact (Gurgaon, Haryana, India; http://www.gcrieber-compact.com/). Each sachet provided the daily dose of supplements. To ensure that the effect of vitamin B12 was not limited by inadequate intake of other essential nutrients, both the placebo and vitamin B12 paste contained a base multi-micronutrient mixture with several other vitamins and minerals at approximately 1 RDA. All caregivers were given dietary recommendations according to national guidelines. Children who developed diarrhea during the intervention period received zinc and oral rehydration solution. Those with mild to moderate anemia (hemoglobin 7 to 10 g/dL) were treated with per oral iron for at least 30 days. Children with pneumonia, dysentery, or other illnesses were treated according to the most recent Integrated Management of Childhood Illness (IMCI) guidelines .
During weekly visits to the homes, field workers asked the mothers about intake of the paste during the past 7 days and recorded in detail the amount of paste given to the children (i.e., half, one-third, three-fourths, or less). All episodes of vomiting or regurgitation after supplementation of the paste were also recorded, and the total number of empty paste sachets were counted at the weekly visits to verify the reported compliance.
The Bayley-III is a comprehensive assessment tool of neurodevelopment in infants and toddlers aged 1 to 42 months . The Bayley-III is often regarded as the gold standard for assessing neurodevelopment in this age-group and is used in research worldwide. We administered the Bayley-III directly with the child at enrollment and end of the study at the study research office. The Bayley-III consists of a cognitive, language (receptive and expressive), motor (fine and gross motor), and socio-emotional scale. Three psychologists, of whom 1 had extensive experience with the Bayley-III, were trained to perform the assessments for the study. To ensure high-quality measurements, we performed standardization exercises in 20 children ahead of the enrollment where the Bayley assessments were scored by 2 raters. The psychologists were required to reach an intra-class correlation coefficient (ICC) >0.90 with the expert rater, who served as the gold standard. Of note, 7% of the sessions during the main study were double scored by the expert rater to ensure appropriate interobserver agreement throughout the study. The ICCs from the quality controls ranged from 0.95 to 0.99 . All the Bayley-III assessments were video-recorded for quality purposes. The Bayley-III raw scores were converted into scaled and composite scores based on U.S. citizen normative data . For the analyses, we used raw, scaled, and composite scores.
Weight was measured with a portable electronic scale (model 877, Seca, California, United States of America) that measures to the nearest 0.01 kg, and length was measured with portable length board (model 417, Seca, California, USA). We measured length and weight at the clinic or at home during the monthly follow-up visits. All anthropometric measurements were performed twice. The mean values were used in the analyses.
Blood samples were collected from the cubital veins into polypropylene tubes containing EDTA (Sarstedt, Germany), which were protected from direct sunlight exposure. Up to 4-mL blood was collected at enrollment and end of study. The hemoglobin concentration was analyzed immediately following blood sampling with HemoCue (HemoCue 201, Ångelholm, Sweden), which was calibrated as per the guidelines defined by the manufacturer. The blood was centrifuged at room temperature for 10 min at 2,000 to 2,500 g within 10 min after venipuncture (Model R-304, Remi, Mumbai, India). Plasma and blood cells were separated, transferred into polypropylene vials (Eppendorf, Germany), and immediately stored at <−80°C until analysis at Bevital Laboratory (Bergen, Norway; www.bevital.no). The samples were shipped to Norway on dry ice by World Courier. The plasma concentrations of cobalamin and folate were determined using microbiological assays [24,25] using a colistinsulfate-resistant strain of Lactobacillus leichmannii or chloramphenicol-resistant strain of Lactobacillus casei, respectively. The functional biomarkers plasma total tHcy and MMA are considered to be sensitive markers of B12 deficiency . Plasma tHcy and MMA were analyzed by gas chromatography-tandem mass spectrometry (GC-MS/MS) based on methylchloroformate derivatization . The within-day coefficient of variation was 4% for both cobalamin and folate and ranged from 1% to 5% for tHcy and MMA. The between-day coefficient of variation was 5% for both cobalamin and folate and ranged from 1% to 8% for MMA and tHcy. We also calculated a combined indicator of cobalamin status (3cB12) based on the 3 biomarkers cobalamin, tHcy, and MMA as suggested by Fedosov and colleagues . In short, this index is the log of the cobalamin concentration divided by the product of the log of the tHcy and MMA concentrations.
The study had 80% power to detect a standardized effect size of 0.22 and had 90% power to detect an effect size of 0.28. In these calculations, we assumed a loss to follow-up of 10%. Details on the samples size calculations are also presented in the previously published protocol paper .
The analyses in this study were carried out according to the predefined protocols and analysis plans (S1–S4 Texts). Weight for age, weight for length, and length for age z-scores were calculated using the most recent WHO growth charts . We defined underweight, stunting, and wasting as z-scores below −2 . We depicted the relationship between changes in vitamin B12 status (i.e., change in the 3cB12 values from baseline to end of study) according to vitamin B12 status (3cB12) at baseline. To do so, we performed a kernel-weighted local polynomial regression of delta 3cB12 on baseline 3cB12 values by treatment group and depicted these dose-response graphs of the predicted values with 95% confidence intervals (CIs). We also compared the concentrations of cobalamin, tHcy, and MMA between the study groups in all infants and according to 3cB12 categories (“possible deficient,” “low,” and “adequate”) at baseline. As these variables were left-skewed, we present the geometric means and the geometric standard deviation factors (GSDFs). We used the log-transformed values of the end-study biomarker concentrations when comparing the differences between the study groups. The exponentials of these mean differences are presented as the geometric mean ratio (GMR) between the study groups.
We compared the mean end-study Bayley-III scaled and composite scores between the intervention groups. For the other outcome variables (Bayley-III raw scores, growth, and hemoglobin concentrations), the effects of the intervention were estimated by comparing the changes from baseline to end study between the study groups. The precision of the effect estimates and corresponding P values were calculated using the Student t test assuming equal variances. We also analyzed the data by several predefined subgroups. The subgrouping variables were stunting (defined as length for age z-scores <−2), underweight (weight for age z-scores <−2), low vitamin B12 status (3cB12 <−0.5), low birth weight (birth weight <2,500 g), anemia (hemoglobin concentration <11.0 g/dL), and exclusive breastfeeding. For these analyses, we used univariate and multiple generalized linear models with the Gaussian distribution family and identity link function adjusting for a set of predefined potential confounders. The following variables were adjusted for in all subgroup analyses: length for age z-scores, maternal and paternal education, and age of the child at baseline. All analyses were performed using Stata version 16 (StataCorp, College Station, Texas, USA).
From April 2015 to February 2017, we screened 733 infants and randomized 600 into the study (Fig 1). A total of 26 infants dropped out due to refusal or migration. Two children were unable to complete the end-study activities, leaving 572 infants with complete neurodevelopmental assessments. We were able to collect and analyze blood samples for biomarker assessments at end study from 567 children.
Baseline features by intervention and placebo groups are presented in Table 1. One in every five infants was born at low birth weight, and one-third were stunted (<−2 z-score length for age) at enrollment. The baseline features were evenly distributed between the intervention groups. The baseline status of vitamin B12 and its plasma biomarkers were also comparable between the intervention groups (S1 Table).
More than 94% of the prescribed doses were reportedly taken (94.3% in the vitamin B12 group and 94.0% in the placebo group; S2 Table). Of these, 86.3% and 84.7% of the vitamin B12 and placebo group, respectively, consumed the entire prescribed doses.
Vitamin B12 supplementation had no effect on any of the neurodevelopmental outcomes (Table 2). For example, the cognitive composite scores were 0.73 points (95% CI: −0.55 to 2.02, P = 0.261) lower in the vitamin B12 group compared to the placebo group. There was also no effect on growth or hemoglobin concentration (Table 3). Children in both groups grew on an average 12.5 cm (SD: 1.8), and the mean difference was 0.20 cm (95% CI: −0.23 to 0.63, P = 0.354). The mean difference in hemoglobin concentration between the groups was 0.02 g/dL (95% CI: −1.33 to 1.37, P = 0.978). The adjusted effects of the interventions on growth and neurodevelopment by various subgroups are shown in S1 and S2 Figs. These analyses did not reveal any variable that modified the effect on any of the outcomes. Unadjusted subgroup analyses yielded the same results. We found no adverse effects of vitamin B12 supplementation (S3 Table).
The effect of vitamin B12 supplementation on B12 status expressed by the 3cB12 according to baseline status is depicted in Fig 2. The distance between the solid and dotted lines represents the metabolic effect of the intervention, which decreased as the baseline vitamin B12 status improved. A similar trend is displayed in S1 Table where the effects on the different biomarkers are shown. For the functional biomarkers, tHcy and MMA, poorer vitamin B12 status at baseline was associated with a larger effect of vitamin B12 supplementation. For example, when restricting the analyses to infants who were classified as possibly deficient, the placebo group had 60% higher MMA concentrations (indicating poorer vitamin B12 status) at end study compared to those in the vitamin B12 group (GMR 1.60, 95% CI: 1.20 to 2.14, P < 0.001). In the children who had adequate status at baseline, there was no effect of vitamin B12 supplementation on the MMA concentration (S1 Table).
The y-axis is the change in 3cB12 from baseline to end study, and the x-axis is the baseline 3cB12 value. The regression lines were generated by a kernel-weighted local polynomial regression with the change in 3cB12 as the dependent variable and 3cB12 at baseline as the independent variable. The shaded areas represent the 95% CI of the regression lines. The profiles were generated separately for the 2 intervention groups, and the distance between the 2 regression lines represents the effect of the vitamin B12 supplementation. The 3cB12 is a function of the plasma concentrations of cobalamin, tHcy, and MMA. CI, 95% confidence interval; MMA, methylmalonic acid; tHcy, total Homocysteine.
In this year-long, double-blind, placebo-controlled RCT, daily intake of a supplement containing vitamin B12 improved vitamin B12 status in marginally stunted Nepalese infants. Those with poor status at the onset of the study benefitted more than those with adequate status. The intervention, however, did not result in any improvements in neurodevelopment, nor was there any effects on growth or hemoglobin concentration. Restricting the analyses to those with poor status at baseline, i.e., those who also had the best metabolic response, did not alter these results.
Our findings are in contrast to results from the observational studies where vitamin B12 status was positively associated with neurodevelopment, growth, and hemoglobin concentration [10,14,30]. The findings are also at odds with results from the 3 small (group sizes of 32 to 104) RCTs in infants and young children where vitamin B12 supplementation resulted in improved developmental scores [15–17].
Several elements of our study design and conduct support the veracity of our findings. The trial enrolled 600 children, of whom >95% could be included in the analyses. As a result, we have precise effect estimates of our primary outcomes, and thus, sufficient power to detect clinically meaningful differences between the treatment groups. The randomization was successful as indicated by no differences in baseline characteristics, and few participants were lost to follow-up. Finally, the compliance with supplement use was high, as it was given on nearly 95% of the scheduled days and resulted in an excellent metabolic response (S2 Table).
The study team has extensive experience with the Bayley-III, and the inter-rater reliability was excellent during both the initial standardization exercises as well as for the quality controls throughout the study. The Bayley-III scores were associated with established risk factors for poor neurodevelopment , which provided support for the validity of the test in this study setting. In addition, the study staff were trained and standardized for 2 decades in measuring infant growth, ensuring precise measurements for these outcomes. Lastly, we had an effective cold chain and used state-of-the-art biochemical methods to estimate the biomarker concentrations ensuring optimal description of the vitamin status.
The participants were moderately stunted infants and accordingly at risk of poor neurodevelopment and vitamin B12 deficiency. Thus, they constituted a group of children where we could expect an effect of vitamin B12 supplementation if subclinical deficiency affected any of our outcomes. For practical and ethical reasons, we could not target children with defined or overt B12 deficiency. We did not have the necessary diagnostic recourses to measure vitamin B12 status before randomization, and giving a placebo to infants with diagnosed vitamin B12 deficiency for a year would violate the principle of clinical equipoise. Thus, the study included some children with adequate vitamin B12 status at baseline. It is plausible that inclusion of vitamin B12 replete children could attenuate a potential effect of the intervention. However, this does not explain our null findings as the effect estimates did not change when we restricted the analyses to those with evidence of deficiency.
A higher dose or a different, more effective, mode of administration (i.e., injection) could have led to different results. The metabolic response, however, indicates a substantial biological effect. Vitamin B12 is involved in 2 biochemical reactions in humans . In 1 of these, vitamin B12 is required for the transfer of methyl groups, which includes remethylation of homocysteine to methionine. Disruption of this pathway increases homocysteine and affects gene regulation and DNA synthesis . Vitamin B12 also acts as an enzymatic cofactor for methylmalonyl-CoA mutase, an enzyme involved in the catabolism of fats and amino acids. Disruption of the latter pathway explains the increased MMA observed in vitamin B12 deficiency. Our study provides causal evidence that both of these metabolic pathways are affected by mild vitamin B12 deficiency in children, and their functioning improves with supplementation. Thus, despite no effects on the clinical outcomes, children in this population could benefit from increasing the vitamin B12 intake as indicated by their improved metabolic profile.
The period of supplementation in the present study might not have covered a critical window where adequate vitamin B12 status is crucial for optimal growth and neurodevelopment. Thus, initiating supplementation sooner, such as before or during pregnancy or earlier in infancy, could have yielded different results.
Restricting the participants to mildly stunted children increased the internal validity and statistical power of our study at the expense of the external validity. In other words, our recruitment strategy reduced the generalizability of our results, which is a limitation. It should be noted that enrolling all infants from the community would result in a larger proportion with adequate vitamin B12 status and, consequently, more children who would not respond to the intervention. A design ensuring higher external validity could accordingly attenuate a potential effect and, at the same time, increase the variability, both contributing to reduced statistical power. Reduced statistical power increases the risk of false-negative results (type II errors), which particularly question null findings such as here. In addition, our study was designed to measure the effects of vitamin B12 supplementation on several outcomes across several subgroups, which reduced the probability of overlooking relevant short-term clinical outcomes.
An important assumption of our study was that the inclusion criteria ensured we targeted those who would benefit from supplementation. It is possible, however, that these stunted children would suffer from deficiencies of other growth-limiting nutrients. We believe this potential bias was accounted for by providing other vitamins and minerals, by treating common infections, and by giving zinc for diarrhea.
In summary, our results show that in Nepalese infants, daily vitamin B12 supplementation improves vitamin B12 status and the metabolic profile expressed by the composite 3cB12 indicator. The metabolic response indicates that this population could benefit from vitamin B12 supplementation, but the clinical consequences of subclinical deficiency in early childhood remain uncertain.
S1 Fig. The effect of vitamin B12 supplementation on the Bayley Scales of Infant Development subscale scores in different subgroups.
A point estimate to the left of the vertical line indicates a beneficial effect of vitamin B12. None of the subgroup specific effects were statistically significant. The effect estimates were calculated with multiple general linear models with the Gaussian distribution family and identity link function adjusting for length for age z-scores, maternal and paternal education, and age of the child at baseline. Stunting and underweight were defined as being <−2 length for age z-scores and weight for age z-scores, respectively. 3cB12: combined vitamin B12 status indicator as suggested by Fedosov and colleagues , low 3cB12 is <−0.5, low birth weight: birth weight <2,500 g, anemia: hemoglobin concentration <11 g/dL.
S2 Fig. The effect of vitamin B12 supplementation on growth and hemoglobin concentration in different subgroups.
A point estimate to the left of the vertical line indicates a beneficial effect of vitamin B12. None of the subgroup specific estimates were statistically significant. The effect estimates were calculated with multiple general linear models with the Gaussian distribution family and identity link function adjusting for length for age z-scores, maternal and paternal education, and age of the child at baseline. Stunting and underweight were defined as being <−2 length for age z-scores and weight for age z-scores, respectively. 3cB12: combined vitamin B12 status indicator as suggested by Fedosov and colleagues , low 3cB12 is <−0.5, low birth weight: birth weight <2,500 g, anemia: hemoglobin concentration <11 g/dL.
S1 Table. Effects of daily vitamin B12 supplementation for 1 year starting in infancy on markers of vitamin B12 status.
S2 Table. Compliance of vitamin B12 supplementation among Nepalese infants participating in clinical trial on the effect of vitamin B12 supplementation on growth, development, and hemoglobin concentration.
S3 Table. Adverse effects of vitamin B12 supplementation among Nepalese infants participating in clinical trial on the effect of vitamin B12 supplementation on growth, development, and hemoglobin concentration.
S1 Text. Main protocol version 1.0.
August 1, 2014.
S2 Text. Main protocol version 2.1.
October 16, 2016.
S3 Text. Plan of analysis version 1.
S4 Text. Plan of analysis version 2.1.
We would like to express our gratitude to all the field staff, children, and families in Bhaktapur who participated in the study. We are also grateful to the Child Health Research Project Team at the Department of Child Health at the Institute of Medicine, Tribhuvan University and Siddhi Memorial Foundation and its founder Shyam Dhaubhadel. Finally, we thank Johanne Haugen who was responsible for randomization.
- 1. Stabler SP, Allen RH. Vitamin B12 deficiency as a worldwide problem. Annu Rev Nutr. 2004;24:299–326. Epub 2004 Jun 11. pmid:15189123.
- 2. Obeid R, Murphy M, Sole-Navais P, Yajnik C. Cobalamin Status from Pregnancy to Early Childhood: Lessons from Global Experience. Adv Nutr. 2017;8(6):971–9. Epub 2017 Nov 17. pmid:29141978; PubMed Central PMCID: PMC5683008.
- 3. Taneja S, Bhandari N, Strand TA, Sommerfelt H, Refsum H, Ueland PM, et al. Cobalamin and folate status in infants and young children in a low-to-middle income community in India. Am J Clin Nutr. 2007;86(5):1302–9. Epub 2007 Nov 10. pmid:17991639
- 4. Ulak M, Chandyo RK, Adhikari RK, Sharma PR, Sommerfelt H, Refsum H, et al. Cobalamin and folate status in 6 to 35 months old children presenting with acute diarrhea in Bhaktapur, Nepal. PLoS ONE. 2014;9(3):e90079. Epub 2014 Mar 7. pmid:24594935; PubMed Central PMCID: PMC3940712.
- 5. van de Rest O, van Hooijdonk LW, Doets E, Schiepers OJ, Eilander A, de Groot LC. B vitamins and n-3 fatty acids for brain development and function: review of human studies. Ann Nutr Metab. 2012;60(4):272–92. pmid:22678093.
- 6. Venkatramanan S, Armata IE, Strupp BJ, Finkelstein JL. Vitamin B-12 and Cognition in Children. Adv Nutr. 2016;7(5):879–88. pmid:27633104; PubMed Central PMCID: PMC5015033.
- 7. Allen LH. Causes of vitamin B12 and folate deficiency. Food Nutr Bull. 2008;29(2 Suppl):S20–34; Discussion S5–7. Epub 2008 Aug 20. pmid:18709879.
- 8. Rosenblatt DS, Whitehead VM. Cobalamin and folate deficiency: acquired and hereditary disorders in children. Semin Hematol. 1999;36:19–34. pmid:9930566
- 9. Dagnelie PC, van Staveren WA. Macrobiotic nutrition and child health: results of a population-based, mixed-longitudinal cohort study in The Netherlands. Am J Clin Nutr. 1994;59(5 Suppl):1187S–96S. pmid:8172122.
- 10. Kvestad I, Hysing M, Shrestha M, Ulak M, Thorne-Lyman AL, Henjum S, et al. Vitamin B-12 status in infancy is positively associated with development and cognitive functioning 5 y later in Nepalese children. Am J Clin Nutr. 2017;105(5):1122–31. Epub 2017 Mar 24. pmid:28330909.
- 11. Louwman MWJ, van Dusseldorp M, van de Vijver FJR, Thomas CMG, Schneede J, Ueland PM, et al. Signs of impaired cognitive function in adolescents with marginal cobalamin status. Am J Clin Nutr. 2000;72:762–9. PubMed PMID: WOS:000089021300016. pmid:10966896
- 12. Strand TA, Taneja S, Kumar T, Manger MS, Refsum H, Yajnik CS, et al. Vitamin B-12, folic Acid, and growth in 6- to 30-month-old children: a randomized controlled trial. Pediatrics. 2015;135(4):e918–26. pmid:25802345.
- 13. Kumar T, Taneja S, Yajnik CS, Bhandari N, Strand TA, Study G. Prevalence and predictors of anemia in a population of North Indian children. Nutrition. 2013. Epub 2014 Feb 25. pmid:24560137.
- 14. Strand TA, Ulak M, Kvestad I, Henjum S, Ulvik A, Shrestha M, et al. Maternal and infant vitamin B12 status during infancy predict linear growth at 5 years. Pediatr Res. 2018;84(5):611–8. PubMed PMID: WOS:000453019100015. pmid:29967525
- 15. Torsvik I, Ueland PM, Markestad T, Bjorke-Monsen AL. Cobalamin supplementation improves motor development and regurgitations in infants: results from a randomized intervention study. Am J Clin Nutr. 2013;98(5):1233–40. pmid:24025626.
- 16. Torsvik IK, Ueland PM, Markestad T, Midttun O, Bjorke Monsen AL. Motor development related to duration of exclusive breastfeeding, B vitamin status and B12 supplementation in infants with a birth weight between 2000–3000 g, results from a randomized intervention trial. BMC Pediatr. 2015;15:218. pmid:26678525; PubMed Central PMCID: PMC4683944.
- 17. Kvestad I, Taneja S, Kumar T, Hysing M, Refsum H, Yajnik CS, et al. Vitamin B12 and Folic Acid Improve Gross Motor and Problem-Solving Skills in Young North Indian Children: A Randomized Placebo-Controlled Trial. PLoS ONE. 2015;10(6):e0129915. Epub 2015 Jun 23. pmid:26098427; PubMed Central PMCID: PMC4476750.
- 18. Strand TA, Ulak M, Chandyo RK, Kvestad I, Hysing M, Shrestha M, et al. The effect of vitamin B12 supplementation in Nepalese infants on growth and development: study protocol for a randomized controlled trial. Trials. 2017;18(1):187. Epub 2017 Apr 23. pmid:28431557; PubMed Central PMCID: PMC5399862.
- 19. Ulak M, Chandyo RK, Thorne-Lyman AL, Henjum S, Ueland PM, Midttun O, et al. Vitamin Status among Breastfed Infants in Bhaktapur, Nepal. Nutrients. 2016;8(3):149. Epub 2016 Mar 24. pmid:27005657; PubMed Central PMCID: PMC4808878.
- 20. Shrestha PS, Shrestha SK, Bodhidatta L, Strand T, Shrestha B, Shrestha R, et al. Bhaktapur, Nepal: the MAL-ED birth cohort study in Nepal. Clin Infect Dis. 2014;59 Suppl 4:S300–3. Epub 2014 Oct 12. pmid:25305301.
- 21. WHO. Integrated Management of Childhood Illness. Geneva: World Health Organization, 2005. Available from: https://apps.who.int/iris/handle/10665/42939.
- 22. Weiss LG, Oakland T, Aylward GP. Bayley-III Clinical Use and Interpretation: Academic Press; 2010.
- 23. Ranjitkar S, Kvestad I, Strand TA, Ulak M, Shrestha M, Chandyo RK, et al. Acceptability and reliability of the Bayley Scales of infant and Toddler Development-III Among Children in Bhaktapur, Nepal. Front Psychol. 2018;9(JUL). PubMed PMID: WOS:000439617100001. pmid:30087639
- 24. Molloy AM, Scott JM. Microbiological assay for serum, plasma, and red cell folate using cryopreserved, microtiter plate method. Methods Enzymol. 1997;281:43–53. pmid:9250965.
- 25. Kelleher BP, Walshe KG, Scott JM, O'Broin SD. Microbiological assay for vitamin B12 with use of a colistin-sulfate-resistant organism. Clin Chem. 1987;33(1):52–4. pmid:3542297.
- 26. Allen RH, Stabler SP, Savage DG, Lindenbaum J. Diagnosis of cobalamin deficiency I: usefulness of serum methylmalonic acid and total homocysteine concentrations. Am J Hematol. 1990;34(2):90–8. pmid:2339683.
- 27. Windelberg A, Arseth O, Kvalheim G, Ueland PM. Automated assay for the determination of methylmalonic acid, total homocysteine, and related amino acids in human serum or plasma by means of methylchloroformate derivatization and gas chromatography-mass spectrometry. Clin Chem. 2005;51(11):2103–9. pmid:16123148.
- 28. Fedosov SN, Brito A, Miller JW, Green R, Allen LH. Combined indicator of vitamin B12 status: modification for missing biomarkers and folate status and recommendations for revised cut-points. Clin Chem Lab Med. 2015;53(8):1215–25. Epub 2015 Feb 27. pmid:25720072.
- 29. Onis M. WHO Child Growth Standards based on length/height, weight and age. Acta Paediatr. 2006;95 (S450):76–85.
- 30. Strand TA, Taneja S, Ueland PM, Refsum H, Bahl R, Schneede J, et al. Cobalamin and folate status predicts mental development scores in North Indian children 12–18 mo of age. Am J Clin Nutr. 2013;97(2):310–7. pmid:23283502.
- 31. Banerjee R. Chemistry and Biochemistry of B12. John Wiley & Sons; 1999.